tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

NurExone’s ExoPTEN Shows Promising Preclinical Results in Spinal Cord Injury Model

Story Highlights
  • NurExone Biologic focuses on regenerative therapies for central nervous system injuries.
  • ExoPTEN demonstrated significant motor function recovery in preclinical spinal cord injury studies.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
NurExone’s ExoPTEN Shows Promising Preclinical Results in Spinal Cord Injury Model

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

NurExone Biologic ( (TSE:NRX) ) has shared an update.

NurExone Biologic Inc. has announced promising preclinical results for its lead product, ExoPTEN, which demonstrated significant improvement in motor function recovery in a spinal cord injury model. The study showed that 100% of animals treated with a high dose of ExoPTEN regained walking ability, highlighting the drug’s potential therapeutic impact and paving the way for further studies and eventual clinical trials.

The most recent analyst rating on (TSE:NRX) stock is a Buy with a C$2.61 price target. To see the full list of analyst forecasts on NurExone Biologic stock, see the TSE:NRX Stock Forecast page.

More about NurExone Biologic

NurExone Biologic Inc. is a biotech company listed on the TSX Venture Exchange, OTCQB, and Frankfurt, focusing on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, targets acute spinal cord and optic nerve injuries, with significant preclinical data supporting its clinical potential in these multi-billion-dollar markets.

Average Trading Volume: 27,286

Technical Sentiment Signal: Strong Buy

Current Market Cap: C$40.36M

Find detailed analytics on NRX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1